Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olorofim vs AmBisome for Invasive Aspergillosis
2024-513030-38-00Phase 3Completed
- Sponsor
- F2G
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, single-blind trial in invasive aspergillosis (IA) comparing Olorofim with AmBisome followed by standard of care (2 arms). Primary endpoint: All-cause mortality rate at Day 42. Started Feb 2022; status: completed.
02
Drugs
olorofim
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on 2024-513030-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513030-38-00.